| CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ... Neurology 78 (10), 690-695, 2012 | 416 | 2012 |
| Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions? AM Bonnet, Y Loria, MH Saint-Hilaire, F Lhermitte, Y Agid Neurology 37 (9), 1539-1539, 1987 | 365 | 1987 |
| Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results JS Fink, JM Schumacher, SL Ellias, EP Palmer, M Saint-Hilaire, ... Cell transplantation 9 (2), 273-278, 2000 | 319 | 2000 |
| Development and validation of an interpretable deep learning framework for Alzheimer’s disease classification S Qiu, PS Joshi, MI Miller, C Xue, X Zhou, C Karjadi, GH Chang, AS Joshi, ... Brain 143 (6), 1920-1933, 2020 | 296 | 2020 |
| Tolcapone improves motor function in parkinsonian patients with the" wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial AH Rajput, W Martin, MH Saint-Hilaire, E Dorflinger, S Pedder Neurology 50 (5_suppl_5), S54-S59, 1998 | 264 | 1998 |
| Environmental, medical, and family history risk factors for Parkinson's disease: a New England‐based case control study CA Taylor, MH Saint‐Hilaire, LA Cupples, CA Thomas, AE Burchard, ... American journal of medical genetics 88 (6), 742-749, 1999 | 256 | 1999 |
| Self‐management rehabilitation and health‐related quality of life in Parkinson's disease: a randomized controlled trial L Tickle‐Degnen, T Ellis, MH Saint‐Hilaire, CA Thomas, RC Wagenaar Movement Disorders 25 (2), 194-204, 2010 | 204 | 2010 |
| A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study JL Li, MR Hayden, EW Almqvist, RR Brinkman, A Durr, C Dodé, ... The American Journal of Human Genetics 73 (3), 682-687, 2003 | 191 | 2003 |
| Association of cumulative lead exposure with Parkinson’s disease MG Weisskopf, J Weuve, H Nie, MH Saint-Hilaire, L Sudarsky, DK Simon, ... Environmental health perspectives 118 (11), 1609-1613, 2010 | 189 | 2010 |
| Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial MA Schwarzschild, A Ascherio, MF Beal, ME Cudkowicz, GC Curhan, ... JAMA neurology 71 (2), 141-150, 2014 | 187 | 2014 |
| Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial S Frank, CM Testa, D Stamler, E Kayson, C Davis, MC Edmondson, ... Jama 316 (1), 40-50, 2016 | 177 | 2016 |
| Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study M Sun, JC Latourelle, GF Wooten, MF Lew, C Klein, HA Shill, LI Golbe, ... Archives of neurology 63 (6), 826-832, 2006 | 169 | 2006 |
| Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study JE Tobin, JC Latourelle, MF Lew, C Klein, O Suchowersky, HA Shill, ... Neurology 71 (1), 28-34, 2008 | 148 | 2008 |
| Effectiveness of an inpatient multidisciplinary rehabilitation program for people with Parkinson disease T Ellis, DI Katz, DK White, TJ DePiero, AD Hohler, M Saint-Hilaire Physical therapy 88 (7), 812-819, 2008 | 131 | 2008 |
| Cerebrospinal fluid, plasma, and saliva in the BioFIND study: relationships among biomarkers and Parkinson's disease features JG Goldman, H Andrews, A Amara, A Naito, RN Alcalay, LM Shaw, ... Movement Disorders 33 (2), 282-288, 2018 | 128 | 2018 |
| Dating the Anthropocene: Towards an empirical global history of human transformation of the terrestrial biosphere EC Ellis, DQ Fuller, JO Kaplan, WG Lutters Elementa 1, 000018, 2013 | 125 | 2013 |
| Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A GA Grillone, DJ Annino Jr, A Blitzer, MF Brin, MH Saint‐Hilaire The Laryngoscope 104 (1), 30-32, 1994 | 123 | 1994 |
| PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study AL DeStefano, MF Lew, LI Golbe, MH Mark, AM Lazzarini, M Guttman, ... The American Journal of Human Genetics 70 (5), 1089-1095, 2002 | 120 | 2002 |
| Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo … PA LeWitt, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, ... The Lancet Neurology 18 (2), 145-154, 2019 | 119 | 2019 |
| The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study JC Latourelle, M Sun, MF Lew, O Suchowersky, C Klein, LI Golbe, ... BMC medicine 6, 1-7, 2008 | 119 | 2008 |
Terry EllisBoston UniversityDirección de correo verificada de bu.edu
